ACE-IPF AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis



Trial Objective

To test the safety and effectiveness of treatment with warfarin, compared to placebo in patients with idiopathic pulmonary fibrosis

Patient Groups:

  • 256 patients will enroll in the study from 22 centers in the United States.
  • 128 patients will receive warfarin and 128 will receive a placebo.

Visits:

  • Screening visit to determine eligibility
  • Study visits every 16 weeks for approximately 3 years
  • Post treatment safety follow up, up to 28 days after treatment discontinuation

Enrollment

Completed and Research Published

How to Participate

For more information, please contact the study coordinator, Todd Dubois at 303.398.1621 or complete the form below.

Who Can Participate

  • Male or female patients between 35 and 80 years of age (Females of childbearing potential must use a reliable method of contraception)
  • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  • Subjects must have progressed despite conventional therapy (standard of care)
  • Diffusion capacity (DLCO) greater than or equal to 35% of predicted value

Trial Location

Main Campus, Denver, CO

Compensation

Not Provided

Trial Sponsors

National Heart Blood and Lung Institute (NHLBI)

Principle Investigators

  • image description
    Kevin Brown, MD